CY1121833T1 - Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης - Google Patents

Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης

Info

Publication number
CY1121833T1
CY1121833T1 CY20191100742T CY191100742T CY1121833T1 CY 1121833 T1 CY1121833 T1 CY 1121833T1 CY 20191100742 T CY20191100742 T CY 20191100742T CY 191100742 T CY191100742 T CY 191100742T CY 1121833 T1 CY1121833 T1 CY 1121833T1
Authority
CY
Cyprus
Prior art keywords
ethoxy
processes
preparation
methanosulfonylethylamine
methoxyphenyl
Prior art date
Application number
CY20191100742T
Other languages
English (en)
Inventor
Jasti VENKATESWARALU
Chinnapillai Rajendiran
Nallamaddi Ravikumar Reddy
Terrence Joseph Connolly
Alexander L. Ruchelman
Jeffrey Eckert
Anthony Joseph Frank
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121833(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of CY1121833T1 publication Critical patent/CY1121833T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/24Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • C07C313/06Sulfinamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται εδώ νέες διεργασίες για την παρασκευή ενδιάμεσων ενώσεων αμινοσουλφόνης για τη σύνθεση 2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλοσουλφονυλαιθυλ]-4-ακετυλαμινοϊσοϊνδολινο-1,3-διόνης, που είναι χρήσιμη για την πρόληψη ή θεραπευτική αγωγή νόσων ή καταστάσεων οι οποίες συσχετίζονται με ένα ανώμαλα υψηλό επίπεδο ή δραστικότητα του TNF-α. Περαιτέρω παρέχονται εδώ διεργασίες για την εμπορική παραγωγή της (S)-1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμίνης.
CY20191100742T 2012-02-21 2019-07-11 Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης CY1121833T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21
PCT/US2013/026780 WO2013126360A2 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine
EP13706898.7A EP2817288B1 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine

Publications (1)

Publication Number Publication Date
CY1121833T1 true CY1121833T1 (el) 2020-10-14

Family

ID=47755073

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100742T CY1121833T1 (el) 2012-02-21 2019-07-11 Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης
CY20201100163T CY1122799T1 (el) 2012-02-21 2020-02-21 Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100163T CY1122799T1 (el) 2012-02-21 2020-02-21 Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης

Country Status (36)

Country Link
US (3) US9187417B2 (el)
EP (4) EP3312156B1 (el)
JP (1) JP2015509496A (el)
KR (1) KR101993248B1 (el)
CN (3) CN107033042A (el)
AR (2) AR090100A1 (el)
AU (1) AU2013203283B2 (el)
BR (3) BR122021020046B1 (el)
CA (1) CA2864517A1 (el)
CO (1) CO7061071A2 (el)
CR (1) CR20140395A (el)
CY (2) CY1121833T1 (el)
DK (2) DK3378850T3 (el)
ES (3) ES2735801T3 (el)
HK (1) HK1205501A1 (el)
HR (2) HRP20191249T1 (el)
HU (2) HUE044192T2 (el)
IL (3) IL234135A (el)
IN (1) IN2014DN06740A (el)
LT (2) LT3312156T (el)
MX (2) MX344190B (el)
MY (1) MY168296A (el)
NI (1) NI201400093A (el)
NZ (1) NZ628028A (el)
PH (1) PH12014501865A1 (el)
PL (2) PL3312156T3 (el)
PT (2) PT3378850T (el)
RS (2) RS59071B1 (el)
RU (1) RU2632875C2 (el)
SG (1) SG11201405035XA (el)
SI (2) SI3378850T1 (el)
TR (1) TR201910430T4 (el)
TW (1) TW201336815A (el)
UA (1) UA116773C2 (el)
WO (1) WO2013126360A2 (el)
ZA (1) ZA201405892B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
AR090100A1 (es) 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
EP3539539A1 (en) 2013-06-17 2019-09-18 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (el) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
WO2016174685A1 (en) * 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
JP2018518489A (ja) * 2015-06-09 2018-07-12 ドクター レディズ ラボラトリーズ リミテッド アプレミラスト及びその中間体の調製方法
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
WO2017085568A1 (en) * 2015-11-19 2017-05-26 Alembic Pharmaceuticals Limited An improved process and novel polymorphic form of apremilast
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
WO2017179065A1 (en) 2016-04-15 2017-10-19 Davuluri Ramamohan Rao Improved process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
CN109890524B (zh) 2016-11-10 2020-08-28 Sms集团有限公司 用于在铸轧设备中制造金属的带材的方法
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
EP3606908B1 (en) 2017-04-04 2020-06-17 Quimica Sintetica, S.A. Resolution of racemic beta-aminosulfone compounds
SI3606907T1 (sl) 2017-04-04 2021-08-31 Quimica Sintetica, S.A. Racemične spojine beta-aminosulfona
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 (s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
NZ331875A (en) 1996-03-22 2000-01-28 Du Pont Pharm Co Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN1802353A (zh) 2002-12-30 2006-07-12 细胞基因公司 氟烷氧基取代的1,3-二氢-异吲哚化合物及其药物用途
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
JP5406215B2 (ja) * 2008-01-25 2014-02-05 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー TNF−α合成の調節因子及びPDE4阻害剤としての三環系化合物
PT2334639E (pt) 2008-09-10 2013-04-26 Celgene Corp Processos para a preparação de compostos de aminossulfona
PL2443089T3 (pl) * 2009-06-18 2014-09-30 Concert Pharmaceuticals Inc Deuterowane pochodne izoindolino-1,3-dionu jako inhibitory pde4 i tnf-alfa
RU2557236C2 (ru) 2009-10-09 2015-07-20 Селджин Корпорейшн Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Also Published As

Publication number Publication date
UA116773C2 (uk) 2018-05-10
EP3702347B1 (en) 2023-11-08
ES2773686T3 (es) 2020-07-14
CN112812044A (zh) 2021-05-18
DK3312156T3 (da) 2019-07-22
LT3378850T (lt) 2020-04-10
RS60036B1 (sr) 2020-04-30
KR20140126389A (ko) 2014-10-30
US9187417B2 (en) 2015-11-17
SI3312156T1 (sl) 2019-09-30
PL3378850T3 (pl) 2020-07-27
RS59071B1 (sr) 2019-09-30
NZ628028A (en) 2016-03-31
PH12014501865B1 (en) 2014-11-17
AR117963A2 (es) 2021-09-08
US9688623B2 (en) 2017-06-27
JP2015509496A (ja) 2015-03-30
ZA201405892B (en) 2015-11-25
EP2817288B1 (en) 2018-05-30
CN104245668A (zh) 2014-12-24
BR112014020444A2 (pt) 2020-10-27
CA2864517A1 (en) 2013-08-29
EP3312156B1 (en) 2019-06-05
HK1205501A1 (en) 2015-12-18
MY168296A (en) 2018-10-23
BR122021020046B1 (pt) 2022-05-31
CN112812044B (zh) 2023-05-30
HUE044192T2 (hu) 2019-10-28
ES2735801T3 (es) 2019-12-20
IL234135A (en) 2017-06-29
MX344190B (es) 2016-12-08
WO2013126360A2 (en) 2013-08-29
CN104245668B (zh) 2017-05-17
DK3378850T3 (da) 2020-03-16
EP3312156A1 (en) 2018-04-25
IL252459A0 (en) 2017-07-31
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
HRP20191249T1 (hr) 2019-10-18
US9586897B2 (en) 2017-03-07
PT3378850T (pt) 2020-03-06
HUE048412T2 (hu) 2020-07-28
AU2013203283B2 (en) 2015-11-26
WO2013126360A3 (en) 2013-10-31
US20130217918A1 (en) 2013-08-22
BR112014020444B1 (pt) 2021-12-07
NI201400093A (es) 2016-11-30
CY1122799T1 (el) 2021-05-05
SI3378850T1 (sl) 2020-07-31
US20170129852A1 (en) 2017-05-11
AU2013203283A1 (en) 2013-09-05
KR101993248B1 (ko) 2019-06-26
EP3702347A1 (en) 2020-09-02
PH12014501865A1 (en) 2014-11-17
TR201910430T4 (tr) 2019-08-21
RU2014138037A (ru) 2016-04-10
CO7061071A2 (es) 2014-09-19
CN107033042A (zh) 2017-08-11
EP3378850A1 (en) 2018-09-26
EP2817288A2 (en) 2014-12-31
ES2675168T3 (es) 2018-07-09
IN2014DN06740A (el) 2015-05-22
PT3312156T (pt) 2019-07-19
TW201336815A (zh) 2013-09-16
MX350731B (es) 2017-09-15
IL273050A (en) 2020-04-30
RU2632875C2 (ru) 2017-10-11
PL3312156T3 (pl) 2019-10-31
BR122021020040B1 (pt) 2022-05-31
EP3378850B8 (en) 2020-03-04
CR20140395A (es) 2014-11-17
SG11201405035XA (en) 2014-09-26
US20160031808A1 (en) 2016-02-04
EP3378850B1 (en) 2020-01-08
HRP20200245T1 (hr) 2020-05-15
AR090100A1 (es) 2014-10-22
IL252459B (en) 2020-03-31

Similar Documents

Publication Publication Date Title
CY1121833T1 (el) Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης
CY1124988T1 (el) Μεθοδοι παρασκευης νεων αναστολεων idh1
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1122964T1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
EA201891879A1 (ru) Иммуномодуляторы
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201791739A1 (ru) Иммуномодуляторы
EA201791708A1 (ru) Иммуномодуляторы
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34374A (es) Benzilindazoles sustituidos
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
UY34591A (es) Compuestos de imidazopirrolidinona
UY34039A (es) Compuestos fungicidas
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CR20110554A (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil-piperazina
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
UY33976A (es) Derivados de pirazolo-pirimidina.
UY34329A (es) Compuestos de triazolopiridina